J. Rick Turner Libros

Focusing on the inferential analysis of data from pharmaceutical clinical trials, the book explores crucial statistical concepts essential for evaluating drug safety and efficacy. It addresses how these analyses inform decision-making at both the public health level, particularly by regulatory agencies, and the individual patient level, involving physicians and patients. Key topics include statistical significance, clinical significance, and the balance of benefits and risks associated with new drug approvals and prescriptions.

Biopharmaceutical drugs improve the health and well-being of people across the globe on a scale that is unrivaled by any other medical intervention. Before these drugs can be prescribed for patients by their doctors, they have to be approved for marketing by a regulatory agency. To gain marketing approval, drugs must go through an extremely rigorous process that investigates their safety and efficacy, the process of New Drug Development. The last stage of this long, complex, and expensive process involves conducting clinical trials, the topic of this book. Successfully conducting clinical trials requires the interdisciplinary collaboration of individuals from many clinical and scientific disciplines and areas of operational expertise. These include medicine, information technology, ethics and law, statistics, clinical trial operations, data collection and management, regulatory science, and medical writing, to name just a few. Central aspects of conducting clinical trials are discussed in the following chapters, with the goals of making specialists from each of these areas aware of the contributions of their colleagues, and helping readers to appreciate that everyone involved in clinical research is working side-by-side toward a common goal---improving the health, well-being, and longevity of millions of patients around the globe.

At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way. Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology.“a resource that will likely serve as a standard for years to come” - Dr Jonathan SeltzerTherapeutic Innovation & Regulatory Science, 2017;51(2):180“I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi ShahJournal for Clinical Studies, 2017;9(1):62-63